New antimicrobial agents for the treatment of Gram-positive bacterial infections

Since the 1970s, resistance to antimicrobial agents has become an escalating problem. In the last 25 years, treatment of infections caused by Gram-positive bacteria has been more problematical than ever, with infections being caused by multidrug-resistant organisms, particularly methicillin-resistan...

Full description

Saved in:
Bibliographic Details
Published inClinical microbiology and infection Vol. 14; no. 5; pp. 411 - 420
Main Authors Aksoy, D.Y., Unal, S.
Format Journal Article
LanguageEnglish
Published Oxford, UK Elsevier Ltd 01.05.2008
Blackwell Publishing Ltd
Blackwell
Subjects
Acetamides - pharmacology
Anti-Infective Agents - pharmacology
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacteria
Biological and medical sciences
Ceftobiprole
Cephalosporins - pharmacology
daptomycin
Daptomycin - pharmacology
Glycopeptides - pharmacology
Gram-Positive Bacterial Infections - drug therapy
Infectious diseases
Linezolid
Medical sciences
Minocycline - analogs & derivatives
Minocycline - pharmacology
Oxazolidinones - pharmacology
Pharmacology. Drug treatments
quinupristin–dalfopristin
review
tigecycline
Virginiamycin - pharmacology
daptomycin
linezolid
quinupristin–dalfopristin
review
tigecycline
Ceftobiprole
Linezolid
Glycylcycline derivatives
Peptides
Daptomycin
Quinupristin
quinupristin-dalfopristin
Antimicrobial agent
Dalfopristin
Infection
Antibiotic
Treatment
Polypeptide
Gram positive bacteria
Oxazolidinone derivative
Streptogramins
Bacteriosis
Protein synthesis inhibitor
Antibacterial agent
Tigecycline
Oxazole derivatives
Lipopeptide
Bibliographic review
Online AccessGet full text

Cover

More Information
Summary:Since the 1970s, resistance to antimicrobial agents has become an escalating problem. In the last 25 years, treatment of infections caused by Gram-positive bacteria has been more problematical than ever, with infections being caused by multidrug-resistant organisms, particularly methicillin-resistant staphylococci, penicillin- and erythromycin-resistant pneumococci, and vancomycin-resistant enterococci. There is a continuing effort in the pharmaceutical industry to develop new antimicrobial agents for the treatment of resistant infections. Linezolid, quinupristin–dalfopristin, daptomycin, tigecyline, new glycopeptides and ceftobiprole are the main agents recently introduced or under clinical development. This review summarises their major properties, the results of recent studies with these agents, and future treatment possibilities.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-3
ObjectType-Review-1
ISSN:1198-743X
1469-0691
DOI:10.1111/j.1469-0691.2007.01933.x